fashion -WSS

fashion

author：Wikipedia 2025-08-12 09:13:02 - browse：317

SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don’t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.

The study, called the Phase 2 Augment-101 trial, tested Syndax’s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study’s presenter, in an interview.

“KMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,” Aldoss said. “The median overall survival remains low with current available treatment. Right now there’s no targeted therapy for KMT2A-rearranged disease. We’re really excited about revumenib as it targets the mutation, and we’re seeing encouraging outcomes.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Stanford president's case begs question: Who takes blame?

WSS

Awakening the world to the whoosh: A patient's crusade

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Awakening the world to the whoosh: A patient's crusade

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

Driven by the pandemic, applicants flood public health schools

Medical school prerequisites are outdated

explore

fashion

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

First transplant of an entire human eye performed

How to save PrEP access — and even expand it

Winning ticket for $1 billion Powerball jackpot sold in California

Medical leaders decry Supreme Court decision on affirmative action

Medical school prerequisites are outdated

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Medicare proposal to cover medical devices draws a mixed reaction

Medicare’s new pay boost for primary care is angering specialists

focus

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Indian pharmaceutical industry in denial over drug

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Carbon Health diabetes program, a test of data

White House drug czar issues call for 'recovery

Medicare’s new pay boost for primary care is angering specialists

hotspot

leisure time

explore

knowledge